MGMT and glioblastoma: The epigenetic regulation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene is the only known determinant of the clinical response to TMZ [3,4,5,6], eventually however, both MGMT methylated and unmethylated GBM develop resistance to TMZ.